HomeCompareCIMEF vs PFE

CIMEF vs PFE: Dividend Comparison 2026

CIMEF yields 2.74% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CIMEF wins by $83.4K in total portfolio value
10 years
CIMEF
CIMEF
● Live price
2.74%
Share price
$1.41
Annual div
$0.04
5Y div CAGR
46.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$133.0K
Annual income
$51,361.74
Full CIMEF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — CIMEF vs PFE

📍 CIMEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCIMEFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CIMEF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CIMEF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CIMEF
Annual income on $10K today (after 15% tax)
$232.70/yr
After 10yr DRIP, annual income (after tax)
$43,657.48/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, CIMEF beats the other by $21,337.58/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CIMEF + PFE for your $10,000?

CIMEF: 50%PFE: 50%
100% PFE50/50100% CIMEF
Portfolio after 10yr
$91.3K
Annual income
$38,810.23/yr
Blended yield
42.53%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

CIMEF
No analyst data
Altman Z
3.2
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CIMEF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCIMEFPFE
Forward yield2.74%6.13%
Annual dividend / share$0.04$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR46.4%13.2%
Portfolio after 10y$133.0K$49.6K
Annual income after 10y$51,361.74$26,258.71
Total dividends collected$104.1K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CIMEF vs PFE ($10,000, DRIP)

YearCIMEF PortfolioCIMEF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,101$400.78$9,153$693.39+$1.9KCIMEF
2$12,487$608.72$8,593$849.25+$3.9KCIMEF
3$14,297$936.84$8,336$1,066.78+$6.0KCIMEF
4$16,766$1,467.71$8,437$1,384.80+$8.3KCIMEF
5$20,294$2,354.87$9,013$1,875.40+$11.3KCIMEF
6$25,615$3,900.08$10,306$2,680.72+$15.3KCIMEF
7$34,143$6,735.20$12,820$4,101.38+$21.3KCIMEF
8$48,817$12,283.38$17,673$6,826.70+$31.1KCIMEF
9$76,263$24,029.11$27,543$12,591.86+$48.7KCIMEF
10$132,963$51,361.74$49,560$26,258.71+$83.4KCIMEF

CIMEF vs PFE: Complete Analysis 2026

CIMEFStock

CIMC Enric Holdings Limited provides transportation, storage, and processing equipment for the clean energy, chemicals, environmental, and liquid food industries worldwide. Its Clean Energy segment manufactures and operates equipment for the storage, transportation, processing, and distribution of compressed natural gas trailers, seamless pressure cylinders, liquefied natural gas trailers and storage tanks, liquefied petroleum gas tanks and trailers, natural gas refuelling station systems, and natural gas compressors; and offers engineering, procurement, and construction services for the natural gas industry, as well as internet of things intelligent operation and management platform under the Anjiehui brand. It offers its products under the Enric, Sanctum, Hongtu, CIMC Tank, Cryobest, Hashenleng, YPDI, CIMC SOE, and CIMC Hydrogen brands. The company's Chemical and Environmental segment offers tank containers for the storage and transportation of liquefied or gasified chemicals under the CIMC Tank and Tankmiles brands. Its Liquid Food segment engineers, manufactures, and sells stainless steel tanks for storage and processing liquid food, such as beer, fruit juice and milk; and provides EPC services for brewery and other liquid food industries under the Ziemann Holvrieka, Briggs of Burton, McMillan, and DME brands. The company also manufactures compressors and accessories, and pressure vessels; offers business solutions for gas equipment; researches and develops technology for natural gas equipment; cryogenic storage and transportation equipment design, manufacture, and technical services; collects, processes, and sells renewable resources; offers terminal and depot, and nonmetallic scrap processing services; and repairs and maintains pressure vessels. The company was incorporated in 2004 and is headquartered in Shenzhen, the People's Republic of China. CIMC Enric Holdings Limited is a subsidiary of China International Marine Containers (Hong Kong) Limited.

Full CIMEF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this CIMEF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CIMEF vs SCHDCIMEF vs JEPICIMEF vs OCIMEF vs KOCIMEF vs MAINCIMEF vs JNJCIMEF vs MRKCIMEF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.